Xilio Therapeutics (XLO)
(Delayed Data from NSDQ)
$0.77 USD
-0.01 (-0.78%)
Updated Sep 24, 2025 04:00 PM ET
After-Market: $0.77 0.00 (0.54%) 5:22 PM ET
3-Hold of 5 3
A Value A Growth C Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
XLO 0.77 -0.01(-0.78%)
Will XLO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for XLO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XLO
Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates
Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates
XLO: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright
Other News for XLO
XLO's price rises by 0.9% on September 23, though its technical setup remains stable.
1,2,3 Pullback Bullish appears for XLO after 1.92% move
Is XLO preparing to trend higher? 1,2,3 Pullback Bullish shows up after rising 2.17%
XLO forms 180 Bullish Setup on September 18
NR7 appears for XLO after 1.58% move